Zoetis, Inc. Hits 52-Week Low at USD 71.48 Amidst Market Decline

Zoetis, Inc., a mid-cap player in the Pharmaceuticals & Biotechnology industry, has reached a new 52-week low of USD 71.48 as of June 30, 2026. This significant decline reflects a challenging year for the company, with a one-year performance drop of 59.82%, contrasting sharply with the S&P 500's gain of 20.86% during the same period. Despite the recent downturn, Zoetis maintains a market capitalization of USD 51,081 million and demonstrates strong management efficiency, evidenced by a return on equity of 80.42%. The company has shown resilience with a healthy annual net sales growth rate of 8.16% and has reported positive results for the last six consecutive quarters. Financial metrics indicate a price-to-earnings ratio of 19.00 and a dividend yield of 1.78%. Additionally, Zoetis has a low debt-to-EBITDA ratio of 1.22, suggesting a strong capacity to manage its debt obligations. While the stock has faced challenges, its operational cash flow reached a high of USD 2,929 million, reflecting its ongoing financial stability.